All
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
AI Insights:
03.17 13:28 UpdatedFair Value Reasoning:
While the market maintains a price of around 7%, fundamental analysis suggests the fair value of 'Yes' is near 0-1%. The core logic is: 1. The rules strictly specify a 'New Coronavirus', excluding currently active Influenza strains (e.g., H5N1, H3N2), which is the primary source of market confusion; 2. There are only about 9 months (approx. 288 days) left in 2026, and there are currently no reports of significant novel coronavirus clusters globally; 3. A WHO pandemic declaration requires strict scientific criteria and time; even if a new virus were identified tomorrow, the probability of it reaching pandemic status within the year is negligible. The current price reflects generalized panic about 'pandemics' and tail-risk hedging rather than rational pricing of the specific pathogen.
Sign up to view more information
Rule Risk
There is a moderate ambiguity risk. The title specifies a 'New Coronavirus Pandemic,' but the rules explicitly exclude 'COVID-19 (SARS-CoV-2)'. The risk lies in how the WHO distinguishes between 'variants' and 'new strains'. If a powerful variant of SARS-CoV-2 emerges with a new name but is technically within the same lineage, or if it's declared an 'endemic' surge rather than a 'pandemic', disputes may arise. Furthermore, 'Pandemic' is a specific official designation by the WHO with a high threshold, and the WHO has historically been cautious in declaring it.
Hedging
Crude Oil
PFE
MRNA
Gold
S&P 500
If the WHO were to declare a new coronavirus pandemic, it would be an extreme Black Swan event. The impact on financial markets would mirror early 2020, causing panic selling in global equities (like the S&P 500) while significantly boosting vaccine and biotech stocks (e.g., Pfizer, Moderna). In commodities, crude oil prices would likely crash due to lockdown expectations, while Gold might rise as a safe haven. The correlation is extremely high, representing a textbook hedging scenario.
Divergence
Significant divergence exists. The prediction market pricing (~7.2%) implies a relatively high short-term outbreak risk, which contradicts the current assessment by the epidemiological community. Mainstream public health focus is currently on H5N1 avian flu cross-species transmission (Influenza), not a novel Coronavirus. The market price incorporates a false beta for 'any pandemic', conflating pathogen classifications, leading to an overvaluation of the 'Yes' option relative to scientific consensus.
